New postpartum depression research from the University of Virginia School of Medicine and Weill Cornell Medicine could lead ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

I was losing touch with reality, and on the sixth morning of our son’s life, I proclaimed to Ross and my mum that I’d ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Destiny's Child alum Michelle Williams thought she "blew it" for her Broadway career when she quit the 2018 production of Once On This Island after two weeks to seek treatment for depression.

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...